X4 Pharmaceuticals (XFOR) Competitors

X4 Pharmaceuticals (NASDAQ:XFOR) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.

Which has more volatility and risk, XFOR or IMAB?

X4 Pharmaceuticals has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Which has stronger valuation & earnings, XFOR or IMAB?

X4 Pharmaceuticals has higher revenue and earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$31.36M	0.51	-$101.17M	$2.14	1.29
I-Mab	$3.27M	23.49	-$206.44M	N/A	N/A

Is XFOR or IMAB more profitable?

I-Mab's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	N/A	-236.19%	-75.14%
I-Mab	N/A	N/A	N/A

Do insiders & institutionals believe in XFOR or IMAB?

72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 2.4% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 22.1% of I-Mab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor XFOR or IMAB?

X4 Pharmaceuticals received 18 more outperform votes than I-Mab when rated by MarketBeat users. Likewise, 68.38% of users gave X4 Pharmaceuticals an outperform vote while only 65.26% of users gave I-Mab an outperform vote.

Company	Underperform	Outperform
X4 Pharmaceuticals	Outperform Votes 80 68.38%	Underperform Votes 37 31.62%
I-Mab	Outperform Votes 62 65.26%	Underperform Votes 33 34.74%

Do analysts rate XFOR or IMAB?

X4 Pharmaceuticals presently has a consensus price target of $72.33, suggesting a potential upside of 2,511.31%. I-Mab has a consensus price target of $5.50, suggesting a potential upside of 483.12%. Given X4 Pharmaceuticals' higher possible upside, equities research analysts clearly believe X4 Pharmaceuticals is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media refer more to XFOR or IMAB?

In the previous week, I-Mab had 3 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 5 mentions for I-Mab and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.79 beat I-Mab's score of 0.77 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
I-Mab	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

X4 Pharmaceuticals and I-Mab tied by winning 8 of the 16 factors compared between the two stocks.